Background Retinopathy of prematurity (ROP) is typically treated with laser
photocoagulation and/or intravitreal anti-vascular endothelial growth factor (anti-VEGF). To …

Purpose To synthesize existing evidence on adverse events, complications, and
unfavorable outcomes of current treatment modalities for treatment-requiring retinopathy of …

The aim of this study is to investigate the nationwide incidence and treatment pattern of
retinopathy of prematurity (ROP) in South Korea. Using the population-based National …

Purpose To focus on the longitudinal evaluation of high-risk infants for the development of
retinopathy of prematurity (ROP) at a single tertiary neonatal intensive care unit (NICU), and …

AIM To compare the efficacy and safety between laser therapy and anti-vascular endothelial
growth factor (VEGF) agents intravitreal injection monotherapy in type-1 retinopathy of …

Retinopathy of prematurity (ROP) is one of the many significant consequences of premature
birth and remains one of the leading causes of visual impairment in infants. Originally …

This retrospective study assesses the clinical features, treatment strategies, and long-term
outcomes of patients with Coats' disease in Korea. Multimodal imaging and medical records …

Oxygen-induced retinopathy (OIR) animal model is widely used for retinopathy of
prematurity (ROP) researches. The purpose of this study was to identify proteins and related …

Purpose: To evaluate the outcome of the combined approach between intravitreal
ranibizumab (IVR) and focal laser photocoagulation (FLP) in the treatment of symptomatic …

Introduction: Bevacizumab and ranibizumab, which are anti-vascular endothelial growth
factor (VEGF) medications, are used frequently in the treatment for retinopathy of prematurity …